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TransplantatABSTRACT
Background. Inflammation, coagulation, and fibrinolysis are tightly linked together.
Reperfusion after transient ischemia activates both neutrophils, coagulation, and fibrino-
lysis. Experimental data suggest that tissue plasminogen activator (tPA) regulates renal
neutrophil influx in kidney ischemia and reperfusion injury.
Methods. In 30 patients undergoing kidney transplantation, we measured renal neutro-
phil sequestration and tPA release from blood samples drawn from the supplying artery
and renal vein early after reperfusion. tPA antigen levels were measured using a com-
mercial enzyme-linked immunosorbent assay kit. For each parameter, transrenal difference
(D) was calculated by subtracting the value of the arterial sample (ingoing blood) from the
value of the venous sample (outgoing blood).
Results. Positive transrenal gradients of tPA antigen occurred at 1 minute [D ¼ 14 (3e46)
ng/mL, P < .01] and 5 minutes [D ¼ 5 (-3 to 27) ng/mL, P < .01] after reperfusion. At 5
minutes after reperfusion, a negative transrenal gradient of neutrophils was observed
[D ¼ -0.17 (-1.45 to 0.24) x 10E9 cells/L, P < .001]. At 1 minute after reperfusion,
neutrophil sequestration into the kidney (ie, negative transrenal neutrophil count)
correlated significantly with tPA release from the kidney (ie, positive transrenal tPA
concentration), (R ¼ -0.513 and P ¼ .006).
Conclusions. The findings suggest a proinflammatory role for tPA in ischemia and
reperfusion injury in human kidney transplantation.The study was supported by grants from Helsinki University
Hospital Research Fund.
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ilmakunnas@hus.fiINFLAMMATION and coagulation are tightly linkedprocesses [1]. Inflammation drives coagulation through
various molecular mechanisms that ultimately lead to
enhanced tissue factor expression and thus activation of
coagulation cascades. Similarly, several factors in the
coagulation and fibrinolytic pathways can trigger either
proinflammatory or anti-inflammatory host responses.
Reperfusion after transient ischemia results in activation
of both inflammation and coagulation. Thus, surgical
ischemia and reperfusion injury (IR-injury) offers a time-
controlled clinical model to study the cross talk between
inflammatory and coagulation pathways in a localizedvier Inc. All rights reserved.
enue, New York, NY 10169
ion Proceedings, 51, 647e650 (2019)environment. We have previously demonstrated the anti-
inflammatory properties of activated protein C in clinical
IR-injury [2e4].0041-1345/19
https://doi.org/10.1016/j.transproceed.2019.01.056
647
648 ILMAKUNNAS, TURUNEN, LINDGREN ET ALTissue plasminogen activator (tPA) catalyzes conversion
of plasminogen to plasmin and thereby enhances fibrino-
lysis. tPA thus has an integral role in limiting thrombus
formation and ensuring blood vessel patency. Beyond its
role in fibrinolysis, tPA has direct immunomodulatory
functions [5]. In experimental models of IR-injury, tPA
regulates tissue neutrophil influx [6e8]. In our kidney
transplantation studies, we obtained data on both
reperfusion-induced graft neutrophil entrapment [9] and
tPA release [10] in the same patient series. Motivated by the
above-mentioned experimental reports, we reanalyzed our
data to seek evidence for the role of tPA in neutrophil
trafficking in vivo in humans.
MATERIALS AND METHODS
The present work is based on 2 previous separate and thorough
publications on neutrophil activation [9] and coagulation [10] in
clinical kidney transplantation. Briefly, the patient series was a
subset of a larger study [11] comparing 3 different regimens of
immunosuppression in renal transplantation with deceased donors:
anti-thymocyte globulin (ATG, Fresenius AG, Bad Homburg,
Germany, group A, n ¼ 15), interleukin 2 receptor antagonist
basiliximab (Simulect, Novartis Pharma AG, Basel, Switzerland,
group B, n ¼ 16) and conventional triple immunosuppression with
cyclosporine, azathioprine, and steroids (group C, n¼ 14). Group A
was omitted because of the strong neutrophil and coagulation and
fibrinolysis activating properties of antithymocyte globulin [9,10].
Groups B and C were pooled together (n ¼ 30) for final analysis.
Paired blood samples were obtained at 1 minute and 5 minutes
after reperfusion from graft-supplying artery and vein (ie, from
recipient’s iliac artery proximal to anastomosis and from the renal
vein of the graft, respectively). Transrenal samples were available in
27 patients at 1 minute and in 28 patients at 5 minutes. A 1-mL
aliquot was kept in an EDTA tube (Vacutainer, Becton Dick-
inson, Franklin Lakes, NJ, USA) in room temperature until
leukocyte counts were analyzed by ADVIA 120 hematology
analyzer (Bayer Corporation, Tarrytown, NY, United States), and a
4-mL aliquot was kept in a prechilled sodium citrate tube (Vacu-
tainer, Becton Dickinson, Franklin Lakes, NJ, United States) and
kept in an ice-water bath (0C) until plasma was separated for
analysis of tPA antigen using a commercial enzyme-linked immu-
nosorbent assay kit (t-PA Actibind, Technoclone, Vienna, Austria).
Transrenal difference (D) was calculated for each parameter by
subtracting the value of the arterial sample (ingoing blood) from the
value of the venous sample (outgoing blood), and the statistical
significance was tested with the nonparametric Wilcoxon and
Mann-Whitney U tests. Correlations were assessed with Pearson
correlation. Categorical data were tested with c2 or Fisher exact
test, as appropriate. Data are presented as median and range.
The amendment of the intervention study plan, permitting
collection of extra samples for this reperfusion study, was approved
by the ethics committee in Helsinki University Hospital. An
informed consent was obtained from the patients before partici-
pating in the study.
RESULTS
All grafts were from deceased heart-beating donors, of
whom 17 were men and 13 women. The donor age was 39
(14e62) years. The graft cold ischemic time was 22.4(13.9e35.5) hours. The age of the recipients (14 men and 16
women) was 45 (26e64) years. The transplantation
indications were as follows: diabetic nephropathy in 9 pa-
tients, polycystic kidney disease in 6 patients, and other
indication in 15 patients. Nine patients presented with
delayed graft function. Serum creatinine at 3 days post-
operatively was 114 (69e475) mmol/L and at 3 months
postoperatively 118 (73e178) mmol/L.
Significant positive transrenal gradients of tPA antigen
were observed both at 1 minute [D ¼ 14 (3e46) ng/mL,
P < .01] and 5 minutes [D ¼ 5 (-3 to 27) ng/mL, P < .01]
after reperfusion [10].
At 1 minute after reperfusion, neutrophil counts did not
change transrenally [D ¼ 0.005 (-0.75 to 0.42) x 10E9 cells/
L], whereas there was marginal but statistically significant
negative transrenal gradient of the monocyte count
[D ¼ 0.02 (-0.1 to 0.2) x 10E9 cells/L, P ¼ .04]. At 5 minutes
after reperfusion, negative transrenal gradients of neutro-
phil [D ¼ -0.17 (-1.45 to 0.24) x 10E9 cells/L, P < .001] and
monocyte counts [D ¼ -0.03 (-0.1 to 0.06) x 10E9 cells/L,
P ¼ .001] were observed [9]. When the patients were
stratified according to the direction of the transrenal
neutrophil gradient (ie, negative or positive), there were no
statistically significant differences in donor, recipient,
operative, or outcome data between the stratified patients
either at 1 minute or 5 minutes after reperfusion (Table 1).
Likewise, no differences were observed if the patients were
stratified according to the transrenal monocyte gradient
(data not shown).
At 1 minute after reperfusion, there was a significant
association (R ¼ -0.513; P ¼ .006) between renal neutrophil
sequestration (ie, negative transrenal neutrophil count) and
renal release of tPA (ie, positive transrenal tPA concen-
tration) (Fig 1). There were no correlations between tPA
and monocyte counts (data not shown).
Transrenal tPA gradient was not associated with post-
operative creatinine levels or delayed graft function (data
not shown).DISCUSSION
Experimental data suggest an active pathophysiological role
for tPA in IR-injury [6e8]. Although tPA itself is not che-
moattractant to neutrophils [6,7], endogenous tPA selec-
tively promotes postischemic tissue neutrophil recruitment
early after reperfusion [6e8]. Kidneys from tPA knockout
mice demonstrated significantly less influx of neutrophils
after ischemia when compared to kidneys of wild-type mice
[6]. Further, prophylactic tPA-antisense oligodinucleotide
treatment reduced renal dysfunction, tubular damage, and
neutrophil influx of similarly challenged kidneys of wild-type
mice [6].
In the present study, high intragraft release of tPA was
associated with kidney neutrophil sequestration. There are
at least 3 possible explanations to the present finding.
Firstly, in clinical thrombolytic therapy, recombinant tPA
activates the complement system [12]. Further, tPA
Table 1. Clinical Characteristics and Transrenal Neutrophil Gradient During Reperfusion
-D PMN, 1 Min þD PMN, 1 Min
P Value*,
1 Min -D PMN, 5 Min þD PMN, 5 Min
P Value*,
5 Min
Donor sex, male/female, n (%) 8 (62)/5 (38) 7 (50)/7 (50) .500 10 (50)/10 (50) 6 (75)/2 (25) .218
Donor age, y 42 (14e62) 43 (18e62) .687 43 (14e62) 39 (22e62) 1.000
Donor cause of death,
trauma/stroke & hemorrhage, n (%)
6 (46)/7 (54) 9 (64)/5 (36) .428 12 (60)/8 (40) 4 (50)/4 (50) .472
Cold ischemic time, h 22.8 (15.9e28.4) 22.4 (13.9e35.5) .390 23.1 (15.9e35.5) 21.6 (13.9.-26.4) .382
Recipient sex, male/female, n (%) 5 (38)/8 (62) 7 (50)/7 (50) .348 11 (55)/9 (45) 2 (25)/6 (75) .155
Recipient age, y 39 (26e64) 44 (29e64) .287 43 (26e64) 47 (29e63) 1.000
Underlying kidney disease,
diabetic/polycystic
/other, n (%)
4 (31)/3 (23)/6 (46) 3 (21)/3 (21)/8 (58) .730 5 (25)/4 (20)/11 (55) 3 (38)/2 (24)/3 (38) .694
Delayed graft function, n (%) 4 (31) 4 (29) .613 5 (25) 3 (38) .442
Serum creatinine at 3 days
postoperatively, mmol/L
102 (76e475) 111 (69e213) .894 106 (69e475) 114 (89e225) .533
Serum creatinine at 3 months
postoperatively, mmol/L
117 (83e144) 113 (73e178) .979 118 (73e178) 106 (88e131) .533
Continuous data are expressed as median (range).
- D PMN denotes negative transrenal neutrophil gradient; þ D PMN denotes positive transrenal neutrophil gradient.
*P values are for -D PMN vs. þD PMN (c2 or Fisher exact test and Mann-Whitney U test, as appropriate).
TPA AND KIDNEY NEUTROPHIL SEQUESTRATION 649facilitates plasminogen activation into plasmin, which then
activates C3 and C5 [13]. Thus, abrupt release of tPA may
result in increased intragraft concentrations of complement
degradation products chemotactic to neutrophils. Secondly,
tPA is expressed on activated neutrophils, and tPA may thus
aid neutrophil extravasation via its direct proteolytic prop-
erties [8]. Thirdly, tPA may increase neutrophil adherence
via plasmin production. Plasmin enhances neutrophil
adhesion by a conformational modification of CD18 on the
neutrophil surface [14]. On the other hand, tPA increases
synthesis of platelet activating factor in the endothelial cells,
resulting in increased P-selectin expression on the endo-
thelium [15]. In the latter study, increased neutrophil
adhesion was promoted also with tPA alone [15]. Further-
more, endogenous tPA regulates the endothelial expressionFig 1. Graft neutrophil infiltration is associated with concomi-
tant graft tPA release at 1 minute after reperfusion. tPA, tissue
plasminogen activator.of platelet-endothelial cell adhesion molecule 1, an adhe-
sion molecule fundamental to neutrophil diapedesis [16].
The action of tPA in reperfusion may be a double-edged
sword. It may break down ischemia-induced microthrombi
[10] and thereby enhance perfusion. On the other hand,
according to the present clinical and previous experimental
data [6e8], tPA increases tissue neutrophil infiltration and
may thus aggravate IR-injury [9,17]. In addition to directly
promoting neutrophil tissue sequestration, tPA extravasated
to the perivascular space activates mast cells (present also in
the kidney) to release lipid mediators such as platelet acti-
vating factor that further attract neutrophils into the post-
ischemic tissue [8].
To the best of our knowledge, this report is the first
clinical in vivo evidence proposing a proinflammatory role
for postischemic tPA release. However, given the post hoc
nature of this data analysis, the present results and the
clinical implications of the phenomenon should be
confirmed in a prospective study in patients undergoing
kidney transplantation.REFERENCES
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